Government Launches Incentive Scheme for Medical Device Manufacturers
In a massive push to fortify India’s medical device ecosystem and champion self-reliance, the Ministry of Chemicals and Fertilisers has officially opened applications for the Scheme for Strengthening of Medical Device Industry (SMDI).
Designed to curb import reliance, accelerate domestic production, and foster innovation, this initiative offers eligible manufacturers substantial financial backing. With total assistance reaching up to ₹10 crore, the scheme provides a critical launchpad for manufacturers looking to scale their operations and invest in the booming Indian MedTech sector.
Contact us to launch your project!
Two Strategic Sub-Schemes Introduced
To address the most pressing gaps in India’s medical device value chain, the government has rolled out two targeted sub-schemes. Together, they aim to bolster both the physical manufacturing infrastructure and the rigorous clinical research required for product commercialization:
- Marginal Investment Scheme for Reducing Import Dependence
- Medical Device Clinical Studies Support Scheme (MDCSS)
Capital Subsidy to Drive Domestic Manufacturing
Under the Marginal Investment Scheme, eligible applicants can secure a one-time capital subsidy of up to ₹10 crore on a reimbursement basis.
This financial support covers critical investments in the manufacturing of raw materials, key components, accessories, and finished medical devices. By offsetting these capital expenditures, the government intends to drastically reduce India’s reliance on imported products, improve supply chain resilience, and empower local manufacturers to compete on a global scale.
₹5 Crore Financial Support for Clinical Studies
Innovation in medical devices requires robust evidence. To support this, the government has introduced the MDCSS, offering up to ₹5 crore in financial assistance (on a reimbursement basis) for regulatory and clinical research.
This funding can be utilized to conduct:
- Clinical Investigations
- Clinical Performance Evaluations
- Post-Market Clinical Follow-up (PMCF) Studies
- Animal Studies
By subsidizing the generation of high-quality clinical evidence, the government is helping Indian manufacturers develop safer, more effective devices that meet stringent domestic and international regulatory standards.
Official Scheme Information: For full eligibility guidelines, criteria details, and official documents, visit the official Department of Pharmaceuticals SMDI Portal.
The Role of Operon Strategist: Turning Opportunity into Reality
As manufacturers prepare to leverage these government incentives, navigating the transition from facility setup to regulatory approval is the ultimate challenge. We bridge the gap between government funding and market readiness through targeted, end-to-end support:
- Maximizing Manufacturing Subsidies: We help you effectively utilize the capital subsidy for new or expanded facilities with specialized Plant Layout Detail Engineering, Product Process Engineering for Manufacturing, and New Product Design Development.
- Securing Clinical & CDSCO Compliance: We streamline your access to MDCSS clinical funding by establishing compliant Quality Management Systems (QMS), building bulletproof Design History Files (DHF), and managing end-to-end CDSCO (India) approvals.
- Driving Global Competitiveness: To fulfill the scheme’s goal of making India a global MedTech hub, we facilitate seamless international expansion through Global Product Registration, including CE Marking (EU MDR / IVDR) and US FDA clearances.